布地奈德/格隆溴铵/福莫特罗治疗老年 COPD 的疗效和安全性。
The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly.
机构信息
Department of Respiration, General Hospital of Pingxiang Mining Industry Group Co., Ltd, Pingxiang 337000, China.
出版信息
Contrast Media Mol Imaging. 2022 Aug 17;2022:8382295. doi: 10.1155/2022/8382295. eCollection 2022.
OBJECTIVE
Chronic obstructive pulmonary disease (COPD) is a major and difficult disease of the chronic respiratory system that is common and frequent, with a huge disease burden. The aim of this study was to investigate the efficacy and safety of budesonide/glyburide/formoterol fumarate (BGF) in the treatment of COPD.
METHODS
A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science. The basic features of the seven pieces of literature were identified using the search strategy. The sample size range was 130∼1264.
RESULTS
The effects of BGF increased FEV1 in patients with COPD (mean difference = 2.86, 95%CI: 2.71-3.01, < 0.00001). The effects of BGF improved in patients with ≥1 TEAE in patients with COPD, and was not statistically significant after treatment (Odds rate = 1.00, 95%CI: 0.85-1.17, =0.97). The effects of BGF increased in patients with TEAEs related a to study treatment in patients with COPD (odds rate = 1.27, 95% CI: 1.03-1.57, =0.02). The effects of BGF in decreased patients with serious TEAEs in patients with COPD (odds rate = -0.02, 95% CI: -0.03--0.00, =0.04). The effects of BGF decreased the death rate in patients with COPD, and were not statistically significant after treatment (odds rate = 0.77, 95% CI: 0.31-1.97, =0.59). The effects of BGF decreased the hypertension rate in patients with COPD (odds rate = 0.92, 95% CI: 0.44-1.89, =0.81), and was not statistically significant after treatment. The effects of BGF increased pneumonia in patients with COPD (odds rate = 1.55, 95% CI: 0.81-2.97, =0.19), and were not statistically significant after treatment. The effects of BGF increased FEV1, increased patients with TEAEs related a to study treatment, and decreased patients with serious TEAEs in patients with COPD.
CONCLUSION
This study elucidates the efficacy and safety of BGF in the treatment of COPD with a view to providing a clinical reference.
目的
慢性阻塞性肺疾病（COPD）是一种常见且多发的严重慢性呼吸系统疾病，具有巨大的疾病负担。本研究旨在探讨布地奈德/吡格列酮/福莫特罗（BGF）治疗 COPD 的疗效和安全性。
方法
在 PubMed、Embase、Cochrane Library 和 Web of Science 中进行全面的文献检索。使用搜索策略确定七篇文献的基本特征。样本量范围为 130∼1264。
结果
BGF 增加了 COPD 患者的 FEV1（平均差值=2.86，95%CI：2.71-3.01，<0.00001）。BGF 改善了≥1 例 TEAE 的 COPD 患者的疗效，治疗后差异无统计学意义（比值比=1.00，95%CI：0.85-1.17，=0.97）。BGF 增加了与研究治疗相关的 COPD 患者的 TEAEs 相关的疗效（比值比=1.27，95%CI：1.03-1.57，=0.02）。BGF 降低了 COPD 患者严重 TEAEs 的发生率，治疗后差异无统计学意义（比值比=-0.02，95%CI：-0.03--0.00，=0.04）。BGF 降低了 COPD 患者的死亡率，但治疗后差异无统计学意义（比值比=0.77，95%CI：0.31-1.97，=0.59）。BGF 降低了 COPD 患者的高血压发生率（比值比=0.92，95%CI：0.44-1.89，=0.81），治疗后差异无统计学意义。BGF 增加了 COPD 患者的肺炎发生率（比值比=1.55，95%CI：0.81-2.97，=0.19），治疗后差异无统计学意义。BGF 增加了 FEV1，增加了与研究治疗相关的 TEAEs，降低了 COPD 患者的严重 TEAEs。
结论
本研究阐明了 BGF 治疗 COPD 的疗效和安全性，以期为临床提供参考。
Zotero 插件